TRT Jatenzo denied as non-formulary by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Jatenzo as Non-Formulary

Aetna's non-formulary denial on Jatenzo means the product is not included on your plan's covered drug list, or is placed on a restricted tier that requires a formulary exception before coverage applies. Aetna's formulary typically includes one or more preferred testosterone products — often a generic injectable or a specific topical formulation — and brand-name oral testosterone products like Jatenzo may not appear as a standard covered option. A formulary exception request, combined with a formal internal appeal, is the correct response.

## Your Federal Appeal Rights

• Formulary exception / internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial. Aetna must respond within 30 days (72 hours expedited).
• External review: After a final internal denial, escalate to an independent review organization within approximately four months. The IRO's decision is binding.
• Expedited track: Request expedited review if you are currently without medication and delay poses a health risk.

## The Formulary Exception Standard

Aetna must approve a formulary exception when the plan's preferred alternatives are clinically inappropriate for you. The core of your appeal is demonstrating — through the prescriber's documentation — why the formulary-preferred testosterone products cannot be substituted for Jatenzo in your specific clinical situation. Relevant clinical grounds include the patient's inability to self-administer injections, documented intolerance or inadequate response to topical formulations, a comorbidity or medication factor documented in the medical record, or the prescriber's clinical judgment that the oral route is the appropriate choice given the patient's profile and the FDA-approved prescribing information.

## What to Gather

1. Prescriber formulary-exception letter — specifically identifies each formulary-preferred testosterone alternative, and explains for each why it is clinically inappropriate or insufficient for this patient. 2. Trial-and-failure records — if the patient previously tried a formulary-preferred product, provide pharmacy records, dates, duration, and documented outcome or adverse response. 3. Clinical rationale for oral route — documentation supporting why Jatenzo's oral formulation is the appropriate delivery route for this patient, referencing the FDA-approved prescribing information. 4. Diagnosis and symptom documentation — confirmed hypogonadism diagnosis and symptomatic presentation consistent with the FDA-approved indication. 5. Applicable guideline reference — generic citation to the Endocrine Society guideline recognizing the range of available testosterone formulations and individualized selection.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria from your plan documents or Aetna's provider portal. Map each criterion:

| Exception Criterion | Your Evidence | |---|---| | Formulary alternative tried and failed | [Product, date, outcome — pharmacy records] | | Formulary alternative clinically inappropriate | [Prescriber letter — specific clinical reasoning] | | Medical necessity of Jatenzo specifically | [Prescriber letter, FDA label reference] |

A peer-to-peer consultation between your prescriber and Aetna's pharmacy medical director is an efficient first step — request this explicitly in your written appeal to expedite resolution.